Quantcast

Latest Neuropathic pain Stories

2014-09-19 08:26:16

SAN FRANCISCO, Sept. 19, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced results from preclinical studies characterizing the analgesic profiles of a series of the company's internally-discovered oral, peripherally-acting kappa opioid receptor agonist molecules. The preclinical research candidates were created using Nektar's small molecule polymer medicinal chemistry platform. The analgesic properties of kappa receptor agonism are well described in the medical...

2014-09-17 12:27:24

MUMBAI, India, September 17, 2014 /PRNewswire/ -- - Glenmark's first in class TRPA1 antagonist, GRC 17536, has shown positive data in a Phase 2a proof of concept study in patients with painful diabetic neuropathy Glenmark Pharmaceuticals today announced that its first in class Transient Receptor Potential Ankyrin 1 (TRPA1) antagonist, GRC 17536 has shown positive data in a Phase 2a double blind, placebo controlled, multi-centre, proof of concept...

2014-09-16 08:29:45

Results Validating the Multi-Modal Mechanism of Action Would Provide the Basis for Differentiating LevoCap ER from other Pain Therapies NEW YORK, Sept. 16, 2014 /PRNewswire/ -- Relmada Therapeutics, Inc., (OTCBB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has entered into an agreement with Memorial Sloan Kettering Cancer Center (MSKCC) in a series of animal studies for levorphanol, the active ingredient of...

2014-09-10 08:30:33

Key Step Accomplished Signals the Initiation of Clinical Development for Potential Blockbuster d-methadone NEW YORK, Sept. 10, 2014 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCBB: RLMD) ("Relmada" or the "Company"), a clinical stage company developing novel therapies for the treatment of chronic pain, today announced that it has filed a Clinical Trial Application (CTA) with Heath Canada to conduct 2 pharmacokinetic studies with d-methadone, its NMDA receptor antagonist for...

2014-09-02 12:28:42

LAS VEGAS, Sept. 2, 2014 /PRNewswire/ -- Millennium Health, a leading health solutions company, will have a significant presence at PAINWeek(®) 2014, the nation's largest annual meeting for frontline clinicians with an interest in pain management. PAINWeek takes place Sept. 2-6 in Las Vegas. http://photos.prnewswire.com/prnvar/20140830/141707 "The healthcare system is constantly trying to strike the right balance between pain treatment and addiction prevention," said Dr. Steven Passik, vice...

2014-07-20 23:02:11

ReportsnReports.com adds “Cebranopadol (Neuropathic Pain) - Forecast and Market Analysis to 202” to its store. Dallas, TX (PRWEB) July 20, 2014 Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. Although the term neuropathic...

2014-07-16 08:27:08

MENLO PARK, Calif., July 16, 2014 /PRNewswire/ -- Virobay, Inc., a clinical stage pharmaceutical company with a platform of cathepsin protease inhibitors being developed for the treatment of neuropathic pain, autoimmune disease and fibrosis, today announced the closing of an expanded Series B second tranche financing of $8.0 million. Including this recent $8 million investment, Virobay has raised an aggregate of $18 million in two tranches of the Series B financing. The first tranche...

2014-06-30 12:31:31

Insurance Giant to Reimburse NYC Rehabilitation Center for Its Calmare Therapy Treatments FAIRFIELD, Conn., June 30, 2014 /PRNewswire/ -- The Calmare(®) Pain Therapy Device, the flagship product of Competitive Technologies, Inc., (OTCQX: CTTC) (CTI), the pain mitigation company, gained a favorable reimbursement ruling from the New York City Civil Courts in a personal injury case against Allstate Insurance, Co., (Allstate). In the ruling, the Court instructed the insurance giant to...

2014-06-26 08:27:08

Top-line results anticipated by end-of-year RALEIGH, N.C., June 26, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has completed enrollment of all patients required for its initial Phase 3 study of Clonidine Topical Gel for the treatment of painful diabetic neuropathy (PDN). http://photos.prnewswire.com/prnvar/20110217/CL49801LOGO The Phase 3 trial is a multicenter, randomized, double-blind, placebo-controlled study to determine the...

2014-06-25 23:08:04

Transparency Market Research has announced the addition of the "Pain Management Therapeutics Market: Global Industry Analysis, Size, Share, Growth and Forecast 2012 - 2018" report to their offering. Browse the full report: http://www.transparencymarketresearch.com/pain-management-therapeutics.html. Albany, New York (PRWEB) June 25, 2014 The global pain management therapeutics market is expected to witness a decline during the forecast period (2012 to 2018) due to patent...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.